Healthcare of Ontario Pension Plan Trust Fund Sells 114,808 Shares of Zoetis Inc. $ZTS

Healthcare of Ontario Pension Plan Trust Fund cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 81.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,513 shares of the company’s stock after selling 114,808 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Zoetis were worth $3,134,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. RFG Advisory LLC lifted its holdings in Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after buying an additional 80 shares during the period. YANKCOM Partnership boosted its stake in Zoetis by 3.5% in the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after acquiring an additional 81 shares during the last quarter. Quest 10 Wealth Builders Inc. grew its holdings in Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after acquiring an additional 86 shares during the period. Financial Engines Advisors L.L.C. raised its position in shares of Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after acquiring an additional 87 shares during the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych raised its position in shares of Zoetis by 20.9% during the 4th quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 520 shares of the company’s stock valued at $65,000 after acquiring an additional 90 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 2.4%

Shares of NYSE ZTS opened at $76.04 on Friday. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $160.48. The stock has a market cap of $31.88 billion, a price-to-earnings ratio of 12.61, a P/E/G ratio of 1.22 and a beta of 0.75. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company’s fifty day moving average is $77.13 and its 200-day moving average is $102.66.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts predict that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Insider Transactions at Zoetis

In other Zoetis news, Director Frank A. Damelio acquired 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 11,650 shares of company stock valued at $886,384 over the last 90 days. 0.22% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. HSBC reduced their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. UBS Group dropped their price objective on Zoetis from $99.00 to $85.00 and set a “neutral” rating for the company in a report on Monday. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Citigroup reduced their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Argus reaffirmed a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $118.33.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.